Spark Therapeutics Inc. will give Roche Holding a chance to make up ground in a field where single treatments may command more than $1 million. It also snaps up an asset that rivals like Novartis might have coveted.
The Bloomington-based maker of medical devices said Wednesday it would appeal the verdict of a federal jury in Indianapolis, which found the device was defectively designed. More than 4,000 patients have filed lawsuits.
The Catalyst Award recognizes companies that excel in addressing recruitment, development and advancement of women. Today, nearly half of Lilly's senior leadership is female, up from 20 percent four years ago.
Connecticut-based Loxo Oncology, which was founded in 2013 and went public a year later, has a cancer drug in development that recently received U.S. Food and Drug Administration "breakthrough therapy" status.
Bristol-Myers and Celgene combined will have nine products with more than $1 billion in annual sales and significant potential for growth in the core disease areas of oncology, immunology and cardiovascular disease.